Nav: Home

Antibiotic envelope markedly cuts risk of cardiac device-related infection

March 18, 2019

NEW ORLEANS (March 17, 2019) -- Encasing cardiac devices such as pacemakers or defibrillators in an "envelope" --a mesh sleeve embedded with antibiotics--reduces the risk of major device-related infection by 40 percent within one year with no increase in complications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

The Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT), which involved nearly 7,000 patients in 25 countries, is the first rigorously designed randomized study to demonstrate the safety and effectiveness of this antibiotic-permeated and bioabsorbable envelope, said Khaldoun G. Tarakji, MD, MPH, associate section head of cardiac electrophysiology at the Cleveland Clinic Heart and Vascular Institute and the study's lead author. It's also one of the largest global randomized controlled trials of a cardiac implantable electronic device ever conducted, he said.

Roughly 1.5 million patients receive a cardiac implantable electronic device worldwide every year. While these devices have improved and extended the lives of millions of patients, infection remains a major, potentially life-threatening complication.

Most infections occur during the first year following implantation, but the risk is not limited to the initial device implantation, Tarakji said. Patients are exposed to this risk every time they need additional device procedures, such as for generator replacement when the battery is depleted, when they need an upgrade of their device or to revise some leads. Therefore, infection is a risk over a lifetime.

When an infection is confirmed, it usually requires the removal of the device and the leads in addition to an extended course of antibiotic therapy. Complication rates with transvenous lead extraction are low, but when they occur, they can be fatal, especially in leads that have been implanted for many years. In addition to the risk of extraction, patients go through prolonged hospitalizations, leaving them vulnerable to additional complications.

"Studies show that even when the device infection is managed properly with successful extraction procedure and the proper antibiotic therapy, short- and long-term mortality remain high in this group of patients," Tarakji said. "Prevention is the cornerstone for addressing device infection. Until now, in addition to adhering to strict sterile surgical techniques, preoperative antibiotics have been the only intervention proven in randomized controlled trial to minimize infection risk. Knowing the consequences, minimizing risk isn't good enough--our goal should be to get the infection rate as close to zero as we can."

A total of 6,983 patients in 25 countries took part in the WRAP-IT trial, which began in 2015. The patients' average age was 70 years and 72 percent were men. Most patients (83 percent) were undergoing a revision, replacement or upgrade of an existing implanted cardiac device, while the rest were receiving their first biventricular pacemaker-defibrillator.

Patients were assigned at random to have their device encased in the antibiotic envelope or not. The antibiotic envelope, made of fully bioabsorbable mesh, is embedded with two antibiotics, rifampin and minocycline, that are slowly released into the pocket where the device is placed over seven days. The envelope itself is fully absorbed by the body at eight to nine weeks after implantation. It comes in two sizes, one for use with pacemakers and one for use with defibrillators. All patients were followed up for one year after their procedure and then every six months until the end of the study. The average length of follow-up was 20.7 months.

To minimize infection risk, all patients--both those receiving the antibiotic envelope and those in the control group--were treated with preoperative antibiotics. Additionally, all surgical teams participating in the study were required to use strict, sterile surgical techniques for every procedure.

The study's primary endpoint was a major device-related infection--defined as an infection resulting in extraction or revision of the device system, long-term antibiotic treatment, or death--within one year of the procedure. Among patients who received the antibiotic envelope, 25 (0.7 percent) developed a major device infection within one year, compared with 42 patients (1.2 percent) in the control group.

"The overall infection rate was lower than expected. This is great news for all electrophysiologists and a testament for the quality of all participating centers in adhering to best practices to minimize infection," Tarakji said. "Even so, using the antibiotic envelope led to an additional 40 percent reduction in major device-related infection during the first year after implantation. And we saw no increase in complications with the use of the envelope, indicating that it is safe to use."

Use of the antibiotic envelope should not replace standard protocols for procedure safety, sound patient selection, the use of preoperative antibiotics and proper surgical techniques. However, the envelope is an additional tool to help drive down the risk of infection after the implantation of a cardiac device, Tarakji said.

The researchers plan to conduct a follow-up study of the cost-effectiveness of using the antibiotic envelope. The large, global patient database that was developed for the WRAP-IT trial may also help to answer other important questions related to device infections, Tarakji said. These questions include whether variations in practice such as the management of different blood-thinning medications and the use of different practices and surgical techniques have any effect on rates of infection.

"We now have a wonderful and rich source of information that we can use to educate ourselves about the association of different practices and variables with device infection," Tarakji said.
-end-
The antibiotic envelope, manufactured by Medtronic, Inc., has been on the market since its approval by the U.S. Food and Drug Administration in 2013. This study was funded by Medtronic, Inc.

This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.

The ACC's Annual Scientific Session will take place March 16-18, 2019, in New Orleans, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC19 for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

American College of Cardiology

Related Antibiotics Articles:

Antibiotics from the sea
The team led by Prof. Christian Jogler of Friedrich Schiller University, Jena, has succeeded in cultivating several dozen marine bacteria in the laboratory -- bacteria that had previously been paid little attention.
Antibiotics not necessary for most toothaches, according to new ADA guideline
The American Dental Association (ADA) announced today a new guideline indicating that in most cases, antibiotics are not recommended for toothaches.
Antibiotics with novel mechanism of action discovered
Many life-threatening bacteria are becoming increasingly resistant to existing antibiotics.
Resistance can spread even without the use of antibiotics
Antibiotic resistance does not spread only where and when antibiotics are used in large quantities, ETH researchers conclude from laboratory experiments.
Selective antibiotics following nature's example
Chemists from Konstanz develop selective agents to combat infectious diseases -- based on the structures of natural products
Antibiotics can inhibit skin lymphoma
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma.
Antibiotics may treat endometriosis
Researchers at Washington University School of Medicine in St. Louis have found that treating mice with an antibiotic reduces the size of lesions caused by endometriosis.
How antibiotics help spread resistance
Bacteria can become insensitive to antibiotics by picking up resistance genes from the environment.
Overuse of antibiotics not what the doctor ordered
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community pharmacies, and the urgent need for better enforcement of laws.
Bacterial armor could be a new target for antibiotics
Boosting efforts to fight antibiotic resistance, Stanford researchers have found that a thin membrane, thought to be just a shrink wrap around some bacterial cell walls, has structural properties critical for survival.
More Antibiotics News and Antibiotics Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab